Identification | Back Directory | [Name]
MK 5172 potassiuM salt | [CAS]
1206524-86-8 | [Synonyms]
MK-5172 Potassium Grazoprevir potassium MK5172 potassiuM salt MK 5172 potassiuM salt MK-5172 (potassiuM salt) Grazoprevir potassiuM salt 2)-ether potassium salt (1:1) Grazoprevir (MK-5172) potassium salt GRAZOPREVIR POTASSIUM SALT;MK5172 POTASSIUM SALT;MK 5172 POTASSIUM SALT (1R,2S)-N-[[[(1R,2R)-2-[5-(3-Hydroxy-6-methoxy-2-quinoxalinyl)pentyl]cyclopropyl]oxy]carbonyl]-3-methyl-L-valyl-(4R)-4-hydroxy-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenylcCyclopropanecarboxamide cyclic (1-2)-ether potassium salt (1:1) | [Molecular Formula]
C38H49N6O9S.K | [MDL Number]
MFCD25976701 | [MOL File]
1206524-86-8.mol | [Molecular Weight]
807.02 |
Hazard Information | Back Directory | [Description]
MK-5172 is a novel P2-P4 quinoxaline macrocyclic HCV NS3/4a protease inhibitor currently in clinical development.
IC50 Value: 7.4 nM and 7 nM for genotype 1b and 1a respectively, in replicon system [1]
Target: HCV NS3/4a protease
| [in vitro]
in vitro: In biochemical assays, MK-5172 was effective against a panel of major genotypes and variants engineered with common resistant mutations observed in clinical studies with other NS3/4a protease inhibitors. In the replicon assay, MK-5172 demonstrated subnanomolar to low-nanomolar EC50s against genotypes 1a, 1b, and 2a [2].
| [in vivo]
in vivo: In rats, MK-5172 showed a plasma clearance of 28 ml/min/kg and plasma half-life of 1.4 hr. When dosed p.o. at 5 mg/kg, the plasma exposure of MK-5172 was good with an AUC of 0.7 uM.hr. The liver exposure of the compound was quite good (23 uM at 4 hr), and MK-5172 remained in liver 24 hr after a single p.o. 5 mg/kg dose. At 24 hr, the liver concentration of MK-5172 was 0.2 uM, which was over 25-fold higher than the IC50 in the replicon assay with 50% NHS. When dosed to dogs, MK-5172 showed low clearance of 5 ml/min/kg and a 3 hr half-life after i.v. 2 mg/kg dosing and had good plasma exposure (AUC=0.4 uM.hr) after a p.o. 1 mg/kg dose [1].
Clinical trial: Evaluation of Hepatic Pharmacokinetics for MK-5172 in Participants With Chronic Hepatitis C . Phase1 | [storage]
Store at -20°C | [References]
References:[1]. Steven Harper , John A. McCauley , Michael T. Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor. ACS Med. Chem. Lett., 2012, 3 (4), pp 332-336
[2]. Summa V, Ludmerer SW, McCauley JA, MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother. 2012 Aug;56(8):4161-7. |
|
Company Name: |
SPIRO PHARMA
|
Tel: |
|
Website: |
www.spiropharma.com.cn |
Company Name: |
BOC Sciences
|
Tel: |
16314854226 |
Website: |
www.bocsci.com |
Company Name: |
Musechem
|
Tel: |
+1-800-259-7612 |
Website: |
www.musechem.com |
|